PHENTERMINE AND NICOTINE FOR SMOKING CESSATION

这项拟议的研究将描述急性和慢性影响 多巴胺释放剂苯丙氨酸和5-羟色胺芬氟拉明 单独或联合使用对吸烟、吸烟反应的释放剂 120名女性的戒断症状和戒烟后体重增加。 芬太尼和芬氟拉明联合给药时，有 已被证明能促进肥胖患者的体重减轻和临床报告 这表明，它们还可以减少对酒精和可卡因的渴望。 因此，这种药物组合也可能有效地减少 尝试吸烟的吸烟者体重增加和渴望 戒烟症状是导致5月份吸烟复发的主要原因 个人。拟议的研究将评估以下方面的效果 芬太尼和芬氟拉明对主观、生理和认知的影响 吸烟对青少年戒烟症状的影响 关注戒烟期间体重增加的女性。科目 会被随机分配来接受芬太尼，芬氟拉明， 芬太尼=芬氟拉明或安慰剂 随后进行了为期六周的临床试验。在实验室会议期间， 受试者将接受单次急性剂量的治疗药物 双盲条件下，会抽一种含有尼古丁的脱毒剂 尼古丁香烟。心理障碍的主观、生理和认知影响 每种香烟的吸烟量都会被测量。在双盲中 临床阶段，受试者将接受为期六周的治疗 无论他们在实验室过程中接受了哪种药物。吸烟 禁欲、戒断症状、体重增加和生理指标 将在六周的治疗期间每周进行一次评估，以及 在之后的一、三、六个月。受试者将收到简报 为戒烟、节食和锻炼提供咨询和支持 临床试验期间的每一次实验室访问。在以下情况下- 上访、吸烟状况、戒断症状和体重将是 被监视着。这项研究的结果将有助于 对香烟神经化学机制的认识 吸烟和戒烟，并可能提供一种新的有效的 戒烟治疗。

The proposed research will characterize the acute and chronic effects of phentermine, a dopamine releaser, and fenfluramine, a serotonin releaser, alone and in combination, on responses to smoking, smoking withdrawal symptoms, and post-cessation weight gain in 120 women. Phentermine and fenfluramine, when administered in combination, have been shown to promote weight loss in obese patients and clinical reports indicate that they may also reduce craving for alcohol and cocaine. Thus, this drug combination may also be efficacious in reducing the weight gain and craving experienced by cigarette smokers attempting to quit, symptoms which are major contributors to smoking relapse in may individuals. The proposed study will evaluate the effects of phentermine and fenfluramine on subjective, physiologic and cognitive effects of smoking, as well as on symptoms of smoking withdrawal in women concerned about weight gain during smoking cessation. Subjects will be randomly assigned to receive either phentermine, fenfluramine, phentermine = fenfluramine, or placebo during one laboratory session followed by a six week clinical trial. During the laboratory session, subjects will receive a single acute dose of the treatment drug under double-blind conditions, and will smoke a nicotine-containing and de- nicotinized cigarette. Subjective, physiologic and cognitive effects of smoking each type of cigarette will be measured. In the double-blind clinical phase, subjects will receive six weeks of treatment with whichever drug they received during the laboratory sessions. Smoking abstinence, withdrawal symptoms, weight gain, and physiologic measures will be assessed at weekly intervals during six weeks of treatment, and at one, three, and six months thereafter. Subjects will receive brief counseling and support for smoking cessation, diet and exercise during each of the laboratory visits during the clinical trial. At the follow- up visits, smoking status, withdrawal symptoms, and weight will be monitored. The results of this study will contribute to the understanding of the neurochemical mechanisms underlying cigarette smoking and smoking cessation, and may provide a new and efficacious treatment for smoking cessation.